Pfizer's Canadian Lipitor Patent Declared Invalid

Law360, New York (January 26, 2007, 12:00 AM EST) -- A Canadian court has shot down Pfizer Inc.’s bid to block Ranbaxy Laboratories Ltd. from marketing a generic version of blockbuster drug Lipitor in Canada until 2010, ruling that a Pfizer patent covering the cholesterol-lowering drug’s active ingredient is invalid.

Thursday, Justice von Finckenstein of the Canadian Federal Court in Toronto denied Pfizer’s request to block the issuance of a Notice of Compliance regarding Pfizer’s Canadian patent—CA 2,021,546—which expires on July 19, 2010.

Justice von Finckenstein held that the ‘546 patent was invalid because it did...
To view the full article, register now.